Literature DB >> 25997377

Evaluation of different inactivation methods for high and low pathogenic avian influenza viruses in egg-fluids for antigen preparation.

Shailesh D Pawar1, Vinay B Murtadak2, Sandeep D Kale2, Prashant V Shinde2, Saurabh S Parkhi2.   

Abstract

In view of the emerging avian influenza (AI) viruses, it is important to study the susceptibility of AI viruses to inactivating agents for preparation of antigens and inactivated vaccines. The available information on susceptibility of both the high and low pathogenic AI viruses to different inactivating agents is inadequate and ambiguous. It has been shown that different subtypes of influenza viruses require different physical and chemical conditions for inactivation of infectivity. The present study was undertaken to evaluate the use of beta-propiolactone (BPL), formalin and ether for inactivation and its impact on antigenicity of AI viruses. A total of nine high and low pathogenic AI viruses belonging to four influenza A subtypes were included in the study. The H5N1 viruses were from the clades 2.2, 2.3.2.1 and 2.3.4. The H9N2 virus included in the study was of the G1 genotype, while the H11N1 and H4N6 viruses were from the Eurasian lineage. The viruses were treated with BPL, formalin and with ether. The confirmation of virus inactivation was performed by two serial passages of inactivated viruses in embryonated chicken eggs. The infectivity of all tested AI viruses was eliminated using 0.1% BPL and 0.1% formalin. Ether eliminated infectivity of all tested low pathogenic AI viruses; however, ether with 0.2% or 0.5% Tween-20 was required for inactivation of the highly pathogenic AI H5N1 viruses. Treatment with BPL, ether and formalin retained virus hemagglutination (HA) titers. Interestingly ether treatment resulted in significant rise in HA titers (P<0.05) of all tested AI viruses. This data demonstrated the utility of BPL, formalin and ether for the inactivation of infectivity of AI viruses used in the study for the preparation of inactivated virus antigens for research and diagnosis of AI.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Avian influenza; BPL; Ether; Formalin; Inactivation

Mesh:

Substances:

Year:  2015        PMID: 25997377     DOI: 10.1016/j.jviromet.2015.05.004

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  20 in total

1.  Multi-clade H5N1 virus-like particles: Immunogenicity and protection against H5N1 virus and effects of beta-propiolactone.

Authors:  Peter Pushko; Irina Tretyakova; Rachmat Hidajat; Xiangjie Sun; Jessica A Belser; Terrence M Tumpey
Journal:  Vaccine       Date:  2018-06-07       Impact factor: 3.641

2.  Genetic characterization of highly pathogenic avian influenza A H5N8 viruses isolated from wild birds in Egypt.

Authors:  Ahmed Kandeil; Ahmed Kayed; Yassmin Moatasim; Richard J Webby; Pamela P McKenzie; Ghazi Kayali; Mohamed A Ali
Journal:  J Gen Virol       Date:  2017-07-19       Impact factor: 3.891

3.  Assessing potential pathogenicity of novel highly pathogenic avian influenza (H5N6) viruses isolated from Mongolian wild duck feces using a mouse model.

Authors:  Bao Tuan Duong; Duc Duong Than; Ulaankhuu Ankhanbaatar; Delgerzul Gombo-Ochir; Gansukh Shura; Amartuvshin Tsolmon; Chris Ka Pun Mok; Ganzorig Basan; Seon Ju Yeo; Hyun Park
Journal:  Emerg Microbes Infect       Date:  2022-12       Impact factor: 19.568

4.  Supplementation of inactivated influenza vaccine with norovirus P particle-M2e chimeric vaccine enhances protection against heterologous virus challenge in chickens.

Authors:  Mohamed Elaish; John M Ngunjiri; Ahmed Ali; Ming Xia; Mahmoud Ibrahim; Hyesun Jang; Jagadish Hiremath; Santosh Dhakal; Yosra A Helmy; Xi Jiang; Gourapura J Renukaradhya; Chang-Won Lee
Journal:  PLoS One       Date:  2017-02-02       Impact factor: 3.240

5.  Synergy between the classical and alternative pathways of complement is essential for conferring effective protection against the pandemic influenza A(H1N1) 2009 virus infection.

Authors:  Ajitanuj Rattan; Shailesh D Pawar; Renuka Nawadkar; Neeraja Kulkarni; Girdhari Lal; Jayati Mullick; Arvind Sahu
Journal:  PLoS Pathog       Date:  2017-03-16       Impact factor: 6.823

6.  Green Tea Catechin-Inactivated Viral Vaccine Platform.

Authors:  Yun H Lee; Yo H Jang; Young H Byun; Yucheol Cheong; Paul Kim; Young J Lee; Yoon J Lee; Je M Sung; Ahyun Son; Hye M Lee; Jinhee Lee; Seung W Yang; Jae-Min Song; Baik L Seong
Journal:  Front Microbiol       Date:  2017-12-12       Impact factor: 5.640

7.  Efficacy and synergy of live-attenuated and inactivated influenza vaccines in young chickens.

Authors:  Hyesun Jang; Mohamed Elaish; Mahesh Kc; Michael C Abundo; Amir Ghorbani; John M Ngunjiri; Chang-Won Lee
Journal:  PLoS One       Date:  2018-04-06       Impact factor: 3.240

8.  In Ovo Delivered Toll-Like Receptor 7 Ligand, Resiquimod Enhances Host Responses against Infectious Bronchitis Corona Virus (IBV) Infection.

Authors:  Upasama De Silva Senapathi; Mohamed Aboelkhair; Kekungu Puro; Mariam Ali; Aruna Amarasinghe; M Sarjoon Abdul-Cader; Guido Van Marle; Markus Czub; Mohamed Faizal Abdul-Careem
Journal:  Vaccines (Basel)       Date:  2020-04-15

9.  Association between Interferon Response and Protective Efficacy of NS1-Truncated Mutants as Influenza Vaccine Candidates in Chickens.

Authors:  Hyesun Jang; John M Ngunjiri; Chang-Won Lee
Journal:  PLoS One       Date:  2016-06-03       Impact factor: 3.240

10.  Antiviral Activities of Hibiscus sabdariffa L. Tea Extract Against Human Influenza A Virus Rely Largely on Acidic pH but Partially on a Low-pH-Independent Mechanism.

Authors:  Yohei Takeda; Yuko Okuyama; Hiroto Nakano; Yasunori Yaoita; Koich Machida; Haruko Ogawa; Kunitoshi Imai
Journal:  Food Environ Virol       Date:  2019-10-16       Impact factor: 2.778

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.